Ganetespib: Phase II started

Synta began the open-label, international Phase II CHIARA trial to evaluate 200 mg/m 2 IV ganetespib given on days 1, 8 and 15 of a 28-day cycle in up to 110 anaplastic lymphoma kinase (ALK)-positive...